高危切缘早期口咽癌和口腔癌术后SBRT:容积旋转调强放疗联合或不联合非共面弧的剂量学比较及STEREOPOSTOP GORTEC 2017-03二期试验的急性毒性结果
STEREOPOSTOP GORTEC 2017-03二期试验的辅助研究纳入10例高危切缘pT1-T2/N0口咽癌和口腔癌术后患者,比较共面弧VMAT(VMATc)与共面加3个非共面弧VMAT(VMATc+nc)的剂量学差异并评估急性毒性。VMATc+nc的梯度指数显著更优(3.45 vs 2.97,p=0.01),多数危及器官受量显著降低;未报告≥4级急性毒性,最常见为≥2级黏膜炎。
要点
- 10例患者接受36 Gy/6次、隔日照射的术后SBRT,比较VMATc与VMATc+nc剂量学。
- VMATc+nc梯度指数显著优于VMATc(3.45 vs 2.97,p=0.01)。
- 未报告≥4级急性毒性,最常见急性毒性为≥2级黏膜炎。
核心结论
- VMATc+nc的剂量学结果优于VMATc,并已成为本研究中心STEREOPOSTOP GORTEC 2017-03试验治疗患者的标准技术。
- 急性毒性看来可接受。
研究设计与样本
- STEREOPOSTOP GORTEC 2017-03二期试验(NCT03401840)的辅助研究,评估高危切缘pT1-T2/N0口咽癌和口腔癌术后SBRT。
- 纳入10例患者,采用Novalis TX®治疗,总剂量36 Gy(100%等剂量线)分6次、隔日照射。
- 每例患者制定两个治疗计划:仅用2个共面弧的VMATc计划与共面加3个非共面弧的VMATc+nc计划。
- 急性毒性按NCI CTCAE V4.03标准评估。
主要发现
- 中位年龄62岁;肿瘤部位为活动舌6例、口底2例、颊部1例、牙龈1例。
- 6例为pT2N0(AJCC第7版),4例为pT1N0;平均CTV和PTV体积分别为36.4 cc和56.1 cc。
- 36 Gy等剂量线平均PTV覆盖率为两种技术均为98.2%(p=ns),适形指数相当(VMATc 1.1 vs VMATc+nc 1.07;p=0.23)。
- VMATc+nc梯度指数显著更优(3.45 vs 2.97;p=0.01),使多数危及器官受量显著降低。
- 口腔、唇和同侧腮腺平均Dmean分别为VMATc 16.8 Gy、11.1 Gy、10.4 Gy vs VMATc+nc 14.8 Gy(p=0.005)、8.1 Gy(p=0.001)、6.5 Gy(p=0.04)。
临床怎么用
- 本研究中心的做法是:VMATc+nc已成为STEREOPOSTOP GORTEC 2017-03试验中治疗患者的标准技术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The STEREO POSTOP GORTEC 2017-03 phase 2 trial (NCT03401840) evaluates postoperative stereotactic body radiotherapy (SBRT) in case of high-risk margins for pT1-T2/N0 oropharyngeal and oral cavity tumors. The present ancillary study aimed to compare the dosimetric impact of adding non-coplanar arcs to the volumetric modulated arc therapy (VMAT) technique and to evaluate acute toxicities on the first patients included in this trial. MATERIALS AND METHODS: Ten patients were included. Patients were treated with Novalis TX®. The total dose was 36 Gy (100 % isodose line) in 6 fractions, treated every other day. Two treatment plans were created for each patient: one plan using 2 coplanar arcs only (VMATc) and one plan using coplanar and 3 non-coplanar arcs (VMATc + nc). Acute toxicity was evaluated according to NCI CTCAE criteria V4.03. RESULTS: Median age was 62 years. Localization of tumor was the mobile tongue for 6 patients, floor of mouth for 2, cheek for 1, and gingiva for 1. Six patients had pT2N0 tumors (AJCC 7th edition) and 4 had pT1N0. Mean CTV and PTV volumes were 36.4 and 56.1 cc respectively. Mean PTV coverage by the 36 Gy isodose was 98.2 % for both techniques (p = ns), with comparable conformity indexes (1.1 for VMATc vs 1.07 for VMATc + nc; p = 0.23). VMATc + nc had a significantly better gradient index (3.45 vs 2.97; p = 0.01), resulting in a significantly better sparing of most organs at risk. For example, mean Dmean to the oral cavity, lips, and homolateral parotid were respectively of 16.8 Gy, 11.1 Gy, and 10.4 Gy for VMATc vs 14.8 Gy (p = 0.005), 8.1 Gy (p = 0.001), 6.5 Gy (p = 0.04) for VMATc + nc. No grade ≥ 4 or higher acute toxicity was reported. The most common acute toxicity was grade ≥ 2 mucositis. CONCLUSION: VMATc + nc had better dosimetric outcomes than VMATc and has become the standard technique for patients treated in the STEREO POSTOP GORTEC 2017-03 trial (NCT03401840) in our institution. Acute toxicity appears acceptable.
引用
- Biau J, Lopez L, Thivat E, et al. Postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high-risk margins: A dosimetric comparison of volumetric modulated arc therapy with or without non-coplanar arcs and acute toxicity outcomes from the STEREOPOSTOP GORTEC 2017-03 phase 2 trial. Clin Transl Radiat Oncol. 2022. PMID: 36466746. doi:10.1016/j.ctro.2022.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。